Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Investor Presentation (December 2025)
17 slides from Moberg Pharma Ab's investor presentation, December 2025
Slide 1: A novel topical treatment for onychomycosis – introducing Terclara
A novel topical treatment for onychomycosis – introducing Terclara® December, 2025
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis Terclara® is a new topical Market approvals Very successful launch in treatment for nail fungus in place in 13 European Scandinavia, European based on terbinafine countries rollout ongoing
Slide 4: Oral terbinafine is the gold standard for treatment of toenail fungus
Oral terbinafine is the gold standard for treatment of toenail fungus x40 Terclara® delivers terbinafine terbinafine in nailbed directly and effectively to the nail with Terclara® vs levels seen with oral treatment* x1,000 76% less terbinafine with Terclara® (MOB-015) in mycological cure* plasma vs
Slide 5: Overview of Phase 3 studies that supported EU approval
Overview of Phase 3 studies that supported EU approval Europe North America Number of patients 452 365 Comparator 8% ciclopirox Vehicle Complete cure @52w Non inferiority met Superiority met Mycological cure rate @52w 84% 70% Improvement of nail condition 70% 82% @12w (patient subjective score) • Pr
Slide 6: Why does Terclara win with patients?
Why does Terclara® win with patients? ▸ Kills the fungus ▸ It is safe ▸ Easy to apply ▸ Quick visible improvement * Mantap marketing survey, 2023
Slide 7: Strong premium position from true advantage
Strong premium position from true advantage Terclara´s mycological cure rate OTC Terabinafin allows for a price premium Mycological cure 76% OTC Amorolfin Mycological cure Mycological cure approx. 20%* Products based on devices Unclear to low cure Cosmetic Medical
Slide 8: 70+ million patients in Europe need better treatment for nail fungus
70+ million patients in Europe need better treatment for nail fungus 10% of the population suffer 7/10 doctors avoid prescribing from nail fungus1 terbinafine tablets2 USD 2bn global onychomycosis market.3 1) PLoS Pathog. 2014 Jun; 10(6): e1004105. 2) due to patients´ concerns for serious side effec
Slide 9: Strong drivers behind underlying market growth
Strong drivers behind underlying market growth 1. High prevalence 2. Aging population 3. Lifestyle factors 4. Growing aesthetic concerns 5. Rising awareness and willingness to treat * Grand View Research, Mordorin Intelligence, GMI, Research & Markets
Slide 10: Terclara expands the market
Terclara® expands the market Terclara’s strong proposition for consumers unlocks the 100% prevalence market growth potential = 100% usage Conversion of non- treaters 44% do not Growth potential treat Conversion Market of “mal- potential treaters” Users of Increased deferior frequency products Satisf
Slide 11: Terclara maintains its market leading position in Sweden as second launch year progresses
Terclara® maintains its market leading position in Sweden as second launch year progresses Terclara® has become the clear market leader and driven category growth – in a highly competitive 47% 40% market 13% Terclara® Terclara® volume value share share no. of units Increase in Terclara® market share
Slide 12: Awarded 'Launch of the year' 2024 by major Swedish pharmacies
Awarded ’Launch of the year’ 2024 by major Swedish pharmacies DOZ pharmacy chain: 'A world class launch that has revitalized the category. The product has quickly become a market leader, driving progress forward and helping us gain market share. With the support of educational materials, we have tog
Slide 13: Terclara market leader also in Norway
Terclara® market leader also in Norway Terclara® launch nominated for “Launch of the Year” by the pharmacy chains Apotek 1 and Alliance Healthcare Builds on the same proven 37% Terclara® 35% Terclara® volume model as the Swedish launch: value share share broad pharmacy distribution, no. of units tar
Slide 14: Terclara is approved in 13 European countries
Terclara® is approved in 13 European countries Market approvals • Austria - OTC • France - Rx • Norway - OTC • Belgium - OTC • Hungary - OTC • Spain - Rx • Czech Rep. - Rx • Ireland - Rx • Sweden - OTC • Denmark - Rx • Italy - OTC • Finland - Rx • Netherlands - OTC Pipeline of additional approvals f
Slide 15: Moberg Pharma, a pharma company with a strong track record
Behind Terclara: Moberg Pharma, a pharma company with a strong track record • Moberg Pharma’s R&D is based on discoveries of late Dr. Sven Moberg of Sahlgrenska University Hospital in Gothenburg, Sweden. • All Moberg Pharma products contains a patented keratolytic carrier which also promotes the vis
Slide 16: Executive summary
Executive summary ► Unprecedented ability to ► Terclara® became the market leader in kill dermatophytes: 76% of patients Sweden and Norway instantly after became fungus free, in two phase 3- starting consumer marketing studies (800+ patients) ► Partners in place for Europe, Canada, ► Terbinafine, th
Slide 17: Thank you!
PHARMA Thank you!
Moberg Pharma — Investor Presentation (December 2025) on 6ix